Genor Biopharma (06998.HK) saw its stock price plummet by 7.40% during intraday trading on Wednesday, as the biotechnology sector in Hong Kong experienced a significant downturn. The sharp decline in Genor's shares reflects a broader trend affecting multiple companies in the biotech industry.

The sell-off in biotech stocks appears to be widespread, with several prominent companies in the sector facing substantial losses. This sector-wide decline suggests that investors may be reassessing their positions in biotechnology firms, possibly due to broader market factors or industry-specific concerns.

Other biotech companies also felt the impact of this downturn. Clover Biopharmaceuticals led the decline with a drop of over 14%, while Canbridge Pharmaceuticals fell nearly 8%. Additionally, Keymed Biosciences and JW (Cayman) Therapeutics experienced losses of 6% and 4% respectively. The simultaneous decline across multiple biotech stocks indicates a potential shift in market sentiment towards the sector as a whole.